Oncology

FDA accepts BLA for BMS’ subcutaneous nivolumab to treat solid tumours

The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) biologics license application (BLA) for the subcutaneous formulation of Opdivo (nivolumab) formulated along with Halozyme’s recombinant human hyaluronidase (rHuPH20) [referred as subcutaneous nivolumab] for previously approved solid tumour indications for the drug.

Celltrion secures new public tenders for two biosimilars in Peru

Biopharmaceutical company Celltrion has solidified its presence in the Latin American pharmaceutical market with a series of successful public tender wins in Peru.

PRISM, ONO to co-create development candidate for oncology target

Biotechnology company PRISM BioLab has signed a target exclusive research and licensing agreement with Japan headquartered company ONO Pharmaceutical for jointly creating a development candidate for the latter’s oncology target.

US FDA accepts sBLA for GSK’s Jemperli for broader endometrial cancer use

GSK has received the US Food and Drug Administration's (FDA) acceptance for its supplemental Biologics License Application (sBLA) for Jemperli (dostarlimab) along with standard-of-care chemotherapy (carboplatin and paclitaxel).

SK pharmteco signs agreement to manufacture Ferring’s ADSTILADRIN

Ferring Pharmaceuticals and SK pharmteco have entered into an agreement to increase commercial manufacturing capacity for Ferring’s ADSTILADRIN (nadofaragene firadenovec-vncg), ensuring a long-term supply of the non-replicating adenoviral vector-based gene therapy.

NICE recommends Novartis’ CAR-T therapy for leukaemia

The UK National Institute for Health and Care Excellence (NICE) has recommended the routine use of Novartis' tisagenlecleucel (Kymriah), a chimeric antigen receptor T-cell (CAR-T) therapy, for children and young adults aged up to 25 years with B-cell acute lymphoblastic leukaemia (ALL).

TORL BioTherapeutics secures $158m for oncology pipeline development

Clinical-stage biotechnology company TORL BioTherapeutics has announced the closure of an oversubscribed $158m Series B-2 financing round.

Teva signs licensing deal with mAbxience for oncology biosimilar candidate

Teva Pharmaceuticals International, a subsidiary of Teva Pharmaceutical Industries, has entered into a strategic licensing agreement with mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma.

Alterome Therapeutics secures $132m in Series B funding

Alterome Therapeutics, a biopharmaceutical company, has closed a $132m Series B financing round.